dexelvucitabine has been researched along with HIV Infections in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (92.31) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grier, JP; Hernandez-Santiago, BI; Mathew, JS; Rapp, KL; Schinazi, RF | 1 |
| Colucci, P; Ducharme, MP; Hoepelman, IM; Pottage, JC; Robison, H; Schürmann, D; Turgeon, J | 1 |
| Mitra, AK; Patel, J | 1 |
| Almond, MR; Liotta, DC; Mao, S; Painter, GR | 1 |
| Otto, MJ | 1 |
| Beard, A; Cartee, L; De La Rosa, A; Kravec, I; McBrayer, TR; Murphy, RL; Otto, MJ; Schinazi, RF; Schürmann, D; Stuyver, LJ | 1 |
| Sax, PE | 1 |
| Susman, E | 1 |
| Feinberg, J | 1 |
| Bacheler, L; Bazmi, H; Diamond, S; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Hammond, J; Klabe, R; Liotta, DC; Manion, DJ; Mellors, J; Otto, MJ; Pierce, M; Rayner, M; Schinazi, RF; Stuyver, L; Trainor, G; Wu, JT; Zhang, H | 1 |
3 review(s) available for dexelvucitabine and HIV Infections
| Article | Year |
|---|---|
ACH-126443 Achillion/Yale University.
Topics: Animals; Clinical Trials as Topic; Hepatitis B; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Technology, Pharmaceutical; Zalcitabine | 2002 |
Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
Topics: Adenine; Cytidine Triphosphate; Deoxycytidine; Deoxycytidine Monophosphate; Deoxyribonucleotides; Dioxolanes; DNA, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; Humans; Kinetics; Molecular Structure; Nucleosides; Organophosphonates; Organophosphorus Compounds; Phosphorylation; Protein Binding; Protein Conformation; Purine Nucleosides; Reverse Transcriptase Inhibitors; Substrate Specificity; Tenofovir; Zalcitabine | 2004 |
New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Cytidine Triphosphate; Deoxycytidine; Dideoxynucleosides; Dioxolanes; Emtricitabine; HIV Infections; Humans; Purine Nucleosides; Reverse Transcriptase Inhibitors; Thionucleosides; Zalcitabine | 2004 |
2 trial(s) available for dexelvucitabine and HIV Infections
| Article | Year |
|---|---|
Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Cytidine Triphosphate; Dose-Response Relationship, Drug; Drug Administration Schedule; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Middle Aged; Reverse Transcriptase Inhibitors; Sequence Analysis, RNA; Viral Load; Zalcitabine | 2004 |
Meeting notes from the 3rd IAS Conference. New drugs.
Topics: Brazil; CCR5 Receptor Antagonists; Congresses as Topic; Cytidine Triphosphate; Darunavir; HIV Infections; Reverse Transcriptase Inhibitors; Sulfonamides; Zalcitabine | 2005 |
8 other study(ies) available for dexelvucitabine and HIV Infections
| Article | Year |
|---|---|
Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cells, Cultured; Drug Interactions; Drug Synergism; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Reverse Transcriptase Inhibitors; Zalcitabine | 2007 |
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
Topics: Anti-HIV Agents; Area Under Curve; Biological Availability; Cohort Studies; Drug Combinations; Half-Life; HIV Infections; HIV-1; Humans; Lopinavir; Models, Statistical; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Zalcitabine | 2009 |
Elvucitabine data released at CROI.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zalcitabine | 2010 |
Meeting notes from ICAAC. D-D4FC (Reverset): further data on treatment-experienced patients.
Topics: Anti-HIV Agents; Cytidine Triphosphate; HIV Infections; Humans; Mutation; Viral Load; Zalcitabine | 2005 |
HIV Pathogenesis and Treatment - Third International AIDS Society Conference.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Chemistry, Pharmaceutical; Clinical Trials as Topic; Congresses as Topic; Darunavir; Drugs, Investigational; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Peptide Fragments; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Rilpivirine; Societies, Scientific; Sulfonamides; Tenofovir; Zalcitabine | 2005 |
dD4FC development discontinued.
Topics: Cytidine Triphosphate; Drug Industry; HIV Infections; Humans; Hyperlipidemias; Reverse Transcriptase Inhibitors; Zalcitabine | 2006 |
DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
Topics: Animals; Anti-HIV Agents; Cytidine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Macaca mulatta; Nucleosides; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2002 |
ViroLogic announces agreement with Achillion.
Topics: Clinical Trials, Phase II as Topic; Cooperative Behavior; Drug Industry; Drug Resistance, Viral; Female; Hepatitis B; HIV Infections; Humans; Zalcitabine | 2002 |